A SYNTHETIC NANOPARTICLE VACCINE FOR THE INDUCTION OF ANTI-NICOTINE ANTIBODIES

该子项目是利用资源的许多研究子项目之一 由NIH/NCRR资助的中心赠款提供。次级项目的主要支助 子项目的主要研究者可能是由其他来源提供的， 包括其他NIH来源。 为子项目列出的总成本可能 表示子项目使用的中心基础设施的估计数量， NCRR赠款不直接向子项目或子项目工作人员提供资金。 Selecta正在开发一种尼古丁疫苗，用于戒烟和预防复发，该疫苗基于其专有的靶向合成疫苗颗粒（tSVP上标TM）技术。本项目旨在评估非人灵长类动物对tSVP尼古丁疫苗的免疫应答。烟草是美国可预防死亡的最大单一原因。烟草使用会导致影响心脏和肺部的疾病，吸烟是心脏病发作、中风、慢性阻塞性肺病和肺气肿的主要危险因素。吸烟还与多种癌症有关，包括肺癌、喉癌和口腔癌以及胰腺癌。 在这个项目中，我们评估了一种新的免疫疗法用于恒河猴戒烟。非人灵长类动物模型是评估对所测试的尼古丁疫苗的免疫应答的最相关的临床前动物模型。除了尼古丁和无活性的生物可降解聚合物外，尼古丁tSVP还含有佐剂和T细胞记忆肽，能够通过MHC II类依赖性途径刺激CD 4 +-T辅助细胞。通过对尼古丁的抗体应答水平（ELISA）来测量实验动物的免疫应答。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Selecta is developing a nicotine vaccine for smoking cessation and relapse prevention based on its proprietary targeted Synthetic Vaccine Particle (tSVP superscript TM technology. The aim of this project is to assess the immune response to tSVP nicotine vaccines in non-human primates. Tobacco is the single greatest cause of preventable death in the United States. Tobacco use causes diseases affecting the heart and lungs, with smoking being a major risk factor for heart attacks, strokes, chronic obstructive pulmonary disease, and emphysema. Smoking has also been linked to a variety of cancers including lung cancer, cancers of the larynx and mouth, and pancreatic cancer. In this project we evaluate a novel immune therapeutic for smoking cessation in rhesus monkeys. The non-human primate model is the most relevant pre-clinical animal model to assess the immune response to the nicotine vaccines being tested. Aside from nicotine and inactive biodegradable polymers, the nicotine tSVPs contain an adjuvant and a T-cell memory peptide able to stimulate CD4+-T helper cells via MHC class II-dependent route. Immune response in experimental animals is measured by the level of antibody response to nicotine (ELISA).